A Metabolomics Approach to Screening for Autism Risk in the Children's Autism Metabolome Project.

Area of Science:

• Biochemistry
• Neuroscience
• Pediatrics

Background:

• Autism spectrum disorder (ASD) is characterized by significant heterogeneity, complicating diagnosis.
• Delayed diagnosis of ASD is a common issue, often due to the complexity of the condition and limitations of current screening tools.
• Identifying reliable biomarkers can stratify ASD into subpopulations, potentially enabling earlier diagnosis and personalized interventions.

Purpose of the Study:

• To identify metabolic alterations (metabotypes) in plasma that can stratify children with ASD into distinct subpopulations.
• To validate the reproducibility of identified metabotypes in an independent cohort.
• To develop and optimize a metabolomic screening battery for ASD detection.

Main Methods:

• Quantitative metabolomic analysis of plasma samples from 708 children (18-48 months) in the Children's Autism Metabolome Project (CAMP).
• Discovery and validation of metabotypes differentiating ASD subjects from typically developing controls using statistical analysis.
• Optimization of a subset of metabotypes into a screening battery to assess sensitivity and specificity.

Main Results:

• Thirty-four candidate metabotypes were identified, differentiating subsets of ASD with high specificity (>95%).
• These metabotypes formed six metabolic clusters based on specific metabolite ratios.
• The optimized screening battery achieved 53% sensitivity and 91% specificity for detecting ASD in the study cohort.

Conclusions:

• Metabolomic screening shows promise for identifying over half of children with ASD.
• This approach may facilitate earlier ASD diagnosis and guide the development of targeted therapeutic strategies.
• Further research into blood-based biomarkers could enhance detection rates and provide deeper biological insights into ASD.